Analysts Expect Collegium Pharmaceutical Inc (COLL) to Post -$0.11 EPS

Share on StockTwits

Wall Street analysts expect Collegium Pharmaceutical Inc (NASDAQ:COLL) to report earnings of ($0.11) per share for the current fiscal quarter, according to Zacks Investment Research. Five analysts have issued estimates for Collegium Pharmaceutical’s earnings, with the lowest EPS estimate coming in at ($0.15) and the highest estimate coming in at ($0.06). Collegium Pharmaceutical reported earnings of ($0.45) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 75.6%. The firm is expected to issue its next quarterly earnings report after the market closes on Thursday, November 8th.

According to Zacks, analysts expect that Collegium Pharmaceutical will report full-year earnings of ($0.63) per share for the current year, with EPS estimates ranging from ($0.72) to ($0.49). For the next fiscal year, analysts expect that the firm will report earnings of $0.60 per share, with EPS estimates ranging from $0.00 to $1.20. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that follow Collegium Pharmaceutical.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Wednesday, August 8th. The specialty pharmaceutical company reported ($0.40) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.42) by $0.02. Collegium Pharmaceutical had a negative net margin of 39.10% and a negative return on equity of 61.82%. The company had revenue of $73.10 million for the quarter, compared to analyst estimates of $72.21 million. The business’s quarterly revenue was up 1930.6% on a year-over-year basis.

A number of research firms have recently commented on COLL. Cantor Fitzgerald set a $35.00 price target on shares of Collegium Pharmaceutical and gave the company a “buy” rating in a research report on Friday, September 21st. ValuEngine lowered shares of Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Tuesday, July 10th. Zacks Investment Research lowered shares of Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Tuesday. BidaskClub lowered shares of Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Tuesday, July 10th. Finally, Janney Montgomery Scott set a $27.00 price target on shares of Collegium Pharmaceutical and gave the company a “buy” rating in a research report on Monday, August 6th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $31.71.

In other news, Director Michael Thomas Heffernan sold 25,000 shares of the firm’s stock in a transaction on Monday, October 15th. The shares were sold at an average price of $16.53, for a total value of $413,250.00. Following the sale, the director now owns 361,000 shares in the company, valued at $5,967,330. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 13.87% of the company’s stock.

Several institutional investors have recently made changes to their positions in COLL. Millennium Management LLC grew its stake in shares of Collegium Pharmaceutical by 1,171.8% in the second quarter. Millennium Management LLC now owns 361,035 shares of the specialty pharmaceutical company’s stock worth $8,611,000 after acquiring an additional 332,647 shares during the last quarter. Summit Trail Advisors LLC boosted its stake in Collegium Pharmaceutical by 2,221.9% during the first quarter. Summit Trail Advisors LLC now owns 332,708 shares of the specialty pharmaceutical company’s stock worth $333,000 after buying an additional 318,379 shares in the last quarter. BlackRock Inc. boosted its stake in Collegium Pharmaceutical by 13.8% during the second quarter. BlackRock Inc. now owns 2,252,273 shares of the specialty pharmaceutical company’s stock worth $53,717,000 after buying an additional 272,302 shares in the last quarter. Macquarie Group Ltd. boosted its stake in Collegium Pharmaceutical by 9.9% during the second quarter. Macquarie Group Ltd. now owns 2,588,356 shares of the specialty pharmaceutical company’s stock worth $61,732,000 after buying an additional 233,598 shares in the last quarter. Finally, Northern Trust Corp boosted its stake in Collegium Pharmaceutical by 78.5% during the second quarter. Northern Trust Corp now owns 526,499 shares of the specialty pharmaceutical company’s stock worth $12,557,000 after buying an additional 231,463 shares in the last quarter. Institutional investors and hedge funds own 93.76% of the company’s stock.

Shares of NASDAQ:COLL traded up $0.46 during trading on Tuesday, reaching $16.95. The stock had a trading volume of 556,723 shares, compared to its average volume of 522,759. Collegium Pharmaceutical has a 52 week low of $9.01 and a 52 week high of $29.90. The firm has a market cap of $544.84 million, a price-to-earnings ratio of -6.86 and a beta of 0.43. The company has a quick ratio of 0.78, a current ratio of 0.82 and a debt-to-equity ratio of 3.94.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.

Recommended Story: Call Option

Get a free copy of the Zacks research report on Collegium Pharmaceutical (COLL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply